Zogenix plans quick return to the FDA with their spurned application on Dravet syndrome drug — shares spike

Zogenix shares are clawing back some of the value they lost 2 months ago after the FDA hit the biotech with a refuse-to-file notice on their experimental therapy for Dravet syndrome.